Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC)

Bioconjugate Chemistry

Volumn 20, Issue 8, 2009, Pages 1625-1633

  Maresca, Kevin P ^a   Hillier, Shawn M ^a   Femia, Frank J ^a   Zimmerman, Craig N ^a   Levadala, Murali K ^b   Banerjee, Sangeeta R ^b   Hicks, Justin ^c   Sundararajan, Chitra ^c   Valliant, John ^c   Zubieta, Jon ^b   Eckelman, William C ^a   Joyal, John L ^a   Babich, John W ^a  

^a Lantheus Medical Imaging   (United States)

^b SYRACUSE UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLATION; CHELATION; LIGANDS; MOLECULAR IMAGING; SYNTHESIS (CHEMICAL); TECHNETIUM; TECHNETIUM COMPOUNDS; TISSUE;

AMINO-ACIDS; CONDITION; DONOR GROUPS; LABELINGS; RADIOCHEMICAL YIELD; RADIOLABELLING; STABILITY DISTRIBUTIONS; TECHNETIUM-; TECHNETIUM-99M; TISSUE DISTRIBUTIONS;

AMINO ACIDS;

ALIPHATIC AMINE; AMINO ACID; AMINO ACID DERIVATIVE; ANION; AROMATIC NITRO COMPOUND; CARBOXYLIC ACID; CATION; CHELATE; LYSINE; METAL; NITROGEN; TECHNETIUM 99M;

ARTICLE; CHELATION; CONJUGATION; CONTROLLED STUDY; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; MALE; MOLECULAR IMAGING; MOLECULE; NONHUMAN; RADIOCHEMISTRY; RAT; SOLID PHASE SYNTHESIS; TISSUE DISTRIBUTION;

RATTUS;

AMINO ACIDS; ANIMALS; CHELATING AGENTS; INTESTINES; ISOTOPE LABELING; KIDNEY; LIVER; LYSINE; MALE; MOLECULAR STRUCTURE; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 70349136310     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900192b     Document Type: Article

References (35)

1. Park, S. I., and Press, O. W. (2007) Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr. Opin. Hematol. 14 (6), 632-638 (Pubitemid 47494079)
2. Matthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S. C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., Hawkins, R. A., and Maris, J. M. (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-meta-iodobenzylguanidine therapy in refractory neuroblastoma. J. Clin. Oncol. 25 (9), 1054-1060 (Pubitemid 46596756)
3. Fitzgerald, P. A., Goldsby, R. E., Huberty, J. P., Price, D. C., Hawkins, R. A., Veatch, J. J., De la Cruz, F., Jahan, T. M., Linker, C. A., Damon, L., and Matthay, K. K. (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose I-131-metaiodobenzylguanidine (I-131-MIBG). Ann. N.Y. Acad. Sci. 1073, 465-490 (Pubitemid 44912041)
4. Frilling, A., Weber, F., Saner, F., Bockisch, A., Hofmann, M., Mueller-Brand, J., and Broelsch, C. E. (2006) Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140 (6), 968-976 (Pubitemid 44937386)
5. Boyd, M., Ross, S., Owens, J., Hunter, D., Babich, J., Zalutsky, M. R., Hamilton, T. G., Bell, S., and Mairs, R. J. (2004) Preclinical evaluation of no-carrier-added [131I] meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett. Drug Des. Discovery 1 (1), 50-57.
6. Mariani, G., Nicolini, M., and Wagner, H. W. (1983) Technetium in Chemistry and Nuclear Medicine, p 131, Vol 1, Cortina International, Verona.
7. Heeg, M. J., and Jurisson, S. (1999) The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc. Chem. Res. 32 (12), 1053-1060.
8. Nicolini, M., Bandoli, G., and Mazzi, U., Eds. (2006) Technetium, Rhenium and Other Metals in Chemistry and Nuclear Mediciine, Vol 7, New York.
9. Jurisson, S. S., and Lyden, J. D. (1999) Potential technetium small molecule radiopharmaceuticals. Chem. Rev. 99, 2205.
10. Liu, S., Edwards, D. S., Harris, A. R., Heminway, S. J., and Barrett, J. A. (1999) Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: synthesis and characterization. Inorg. Chem. 38 (6), 1326-1335.
11. Schweinsberg, C., Maes, V., Brans, L., Blauenstein, P., Tourwe, D. A., Schubiger, P. A., Schibli, R., and Garayoa, E. G. (2008) Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjugate Chem. 19 (12), 2432-2439.
12. 3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression. J. Nucl. Med. 49 (6), 970-977.
13. Chen, X., Dou, S., Liu, G., Liu, X., Wang, Y., Chen, L., Rusckowski, M., and Hnatowich, D. J. (2008) Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjugate Chem. 19 (8), 1518-1525.
14. Hom, R. K., and Katzenellenbogen, J. A. (1997) Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl. Med. Biol. 24 (6), 485-498.
15. Fitzsimmons, J. M., and Lever, S. Z. (2004) Synthesis and characterization of metal complexes designed to retain affinity for the sigma receptor, Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, NUCL-002.
16. Katzenellenbogen, J. A., Welch, M. J., and Dehdashti, F. (1997) The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 17 (3B), 1573-1576. (Pubitemid 27263124)
17. James, S., Maresca, K., Babich, J., Valliant, J., Doering, L., and Zubieta, J. (2006) Isostructural Re and 99mTc complexes of biotin derivatives for fluorescence and radioimaging studies. Bioconjugate Chem. 17 (3), 590-596. (Pubitemid 43794367)
18. Bursavich, M. G., and Rich, D. H. (2002) Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 45 (3), 541-558
19. Hirschmann, R., Nicolaou, K. C., Pietranico, S., Leahy, E. M., Salvino, J., Arison, B., Cichy, M. A., Spoors, P. G., Shakespeare, W. C., Sprengeler, P. A., Hamley, P., Smith III, A. B., Reisine, T., Raynor, K., Maechler, L., Donaldson, C., Vale, W., Freidinger, R. M., Cascieriand, M. R., and Strader, C. D. (1993) De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing &D-glucose as a novel scaffolding. J. Am. Chem. Soc. 115, 12550-12568. (Pubitemid 24077506)
20. Rajagopalan, R., Grummon, G. D., Bugaj, J., Hallemann, L. S., Webb, E. G., Marmion, M. E., Vanderheyden, J. L., and Srinivasan, A. (1997) Preparation, characterization, and biological evaluation of technetium(V) and rhenium(V) complexes of novel heterocyclic tetradentate N3S ligands. Bioconjugate Chem. 8 (3), 407-415. (Pubitemid 27236507)
21. Pollak, A., Roe, D. G., Pollock, C. M., Lu, L. F., and Thornback, J. R. (1999) A convenient method of preparing high specific activity technetium complexes using thiol-containing chelators adsorbed on gold. J. Am. Chem. Soc. 121 (49), 11593-11594. (Pubitemid 30010502)
22. 99mTc labeling. Nucl. Med. Biol. 28 (6), 703-708.
23. - in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987.
24. 3]+ (M = Re, Tc) directed towards radiopharmaceutical application. Coord. Chem. Rev. 190-192, 901-919.
25. Schibil, R., La Bella, R., Alberto, R., Garcia-Garayoa, E., Ortner, K., Abram, U., and Schubiger, P. A. (2000) Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjugate Chem. 11, 345-351. (Pubitemid 30324900)
26. + core. Bioconjugate Chem. 19 (12), 2409-2416.
27. + labeled N,N-bis(2-pyridylmethyl)-4-aminobutyric acid. Bioconjugate Chem. 15 (6), 1441-1446.
28. Lipowska, M., Marzilli, L. G., and Taylor, A. T. (2009) 99mTc(CO)3-nitrilotriacetic acid: a new renal radiopharmaceutical showing pharmacokinetic properties in rats comparable to those of 131I-OIH. J. Nucl. Med. 50, 454-460.
29. Bartholomae, M., Valliant, J., Maresca, K. P., Babich, J. W., and Zubieta, J. (2009) Single amino acid chelates: a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem. Commun. 5, 493-512.
30. Stephenson, K. A., Zubieta, J., Banerjee, S. R., Levadala, M. K., Taggart, L., Ryan, L., McFarlane, N., Boreham, D. R., Maresca, K. P., Babich, J. W., and Valliant, J. F. (2004) A new strategy for the preparation of peptide-targeted radiopharmaceuticals based on an Fmoc-lysine-derived single amino acid chelate (SAAC). Automated solid-phase synthesis, NMR characterization, and in vitro screening of fMLF(SAAC)G and fMLF[(SAAC-Re(CO)3) +]G. Bioconjugate Chem. 15 (1), 128-136. (Pubitemid 38180422)
31. 99mTc complexes for correlating fluorescence and radioimaging studies. J. Am. Chem. Soc. 126 (28), 8598-8599.
32. 99mtechnetium(I) heart agents. Inorg. Chem. Commun. 10 (12), 1409-1412.
33. Levadala, M. K., Banerjee, S. R., Maresca, K. P., Babich, J. W., and Zubieta, J. (2004) Direct reductive alkylation of amino acids: Synthesis of bifunctional chelates for nuclear imaging. Synthesis 11, 1759-1766.
34. Matos, K., Pichlmair, S., and Burkhardt, E. R. (2007) Boron reagents for reductive amination. Chim. Oggi. 25 (1), 17-20.
35. Maresca, K. P., Hillier, S. M., Femia, F. J., Keith, D., Barone, C., Joyal, J. L., Zimmerman, C. N., Kozikowski, A. P., Barrett, J. A., Eckelman, W. C., and Babich, J. W. (2009) A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem. 52 (2), 347-357.